New Jersey A4190 codifies regulations on controlled dangerous substances and prescription monitoring.
New Jersey A4190 codifies certain regulatory provisions regarding controlled dangerous substances and prescription monitoring. The bill mandates that practitioners discuss pain management plans, patient rights, and obligations with patients before prescribing Schedule II controlled dangerous substances. It requires practitioners to enter into a pain management agreement with patients for chronic pain treatment and to periodically review and document treatment progress.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.